Key terms
About PODD
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PODD news
Apr 08
6:29am ET
SPY ETF Update, 4/8/2024
Apr 04
2:36am ET
SPY ETF Update, 4/4/2024
Apr 02
7:25am ET
SPY ETF Update, 4/2/2024
Mar 29
4:58am ET
SPY ETF Update, 3/29/2024
Mar 25
2:49am ET
SPY ETF Update, 3/25/2024
Mar 22
7:20am ET
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Mar 21
7:40am ET
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)
Mar 21
5:55am ET
SPY ETF Update, 3/21/2024
Mar 20
7:23am ET
Insulet Appoints Ana Maria Chadwick as New CFO
Mar 20
6:02am ET
Insulet appoints Ana Maria Chadwick as CFO
Mar 16
12:15pm ET
Insulet’s Growth Trajectory Affirmed with a Buy Rating and Revised Target Price
Mar 16
12:15pm ET
Insulet price target lowered to $250 from $260 at Citi
Mar 08
6:02am ET
Insulet reports ‘positive’ results from Omnipod 5 trial
Mar 07
6:00am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP)
Mar 05
12:15am ET
SPY ETF Update, 3/5/2024
Mar 01
4:12pm ET
Insulet Enhances Equity Agreements and Compliance for 2024
Mar 01
10:50am ET
Insulet participates in a conference call with JPMorgan
Mar 01
4:55am ET
Insulet participates in a conference call with JPMorgan
Feb 29
5:13pm ET
Insulet participates in a conference call with JPMorgan
Feb 26
5:51am ET
Insulet price target lowered to $213 from $214 at Barclays
Feb 25
11:40pm ET
Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)
Feb 25
11:36pm ET
Insulet’s Strong Growth and Market Position Justify Buy Rating Despite Short-Term Revenue Guidance Concerns
Feb 25
8:15pm ET
Barclays Sticks to Its Hold Rating for Insulet (PODD)
Feb 23
7:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD)
Feb 23
7:40am ET
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY)
Feb 23
7:20am ET
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Insulet (PODD) and Teleflex (TFX)
Feb 23
7:20am ET
Piper Sandler Remains a Buy on Insulet (PODD)
Feb 23
7:11am ET
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Cogent Biosciences (COGT)
Feb 23
5:55am ET
Insulet’s Strong Performance and Promising Outlook Merit a Buy Rating
Feb 23
12:20am ET
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Teleflex (TFX) and Madrigal Pharmaceuticals (MDGL)
Feb 22
4:09pm ET
Insulet sees FY24 revenue growth 12%-17%, consensus $1.98B
No recent press releases are available for PODD
PODD Financials
Key terms
Ad Feedback
PODD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PODD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range